Day Zero Diagnostics Inc. and Oxford Nanopore Technologies plc (ONT) joined forces to battle the leading cause of death in hospitals — sepsis. Combining Day Zero’s whole genome sequencing technology for pathogen identification and antimicrobial susceptibility analysis with Oxford’s nanopore-based molecular sensing technology, the companies aim to develop a diagnostic system that provides potentially life-saving identification and guidance on antimicrobial selection in mere hours. Read More
In the following years, 2023 may come to be seen in medical device circles as the year of artificial intelligence (AI), but that doesn’t mean that 2023 will be seen as the year of regulatory clarity for AI. Read More
Senior leaders and investors in the health care sector expect mergers and acquisitions (M&A) activity to continue to pick up next year but this will be corporate led rather than private equity, according to a report by global investment bank Jefferies. At the same time, many executives remained concerned about the lack of funding in the sector as it was identified as the number one threat. Read More
Researchers from the Weizmann Institute of Science in Rehovot, Israel, are seeking – through the university’s commercial arm, Yeda Research and Development Co. Ltd. – to gain patent protection for methods and systems for detecting and treating attention deficit hyperactivity disorder (ADHD) that are based on nasal respiration parameters. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: AIQ, Asensus, Blackford, Centinel Spine, Concertai, Merck, Nateria, Pixium, Progentec, Talis Biomedical. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biocardia, Brixton, Lunit, Mednition, Vyspine. Read More
